Drugs / IVS-3001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05672459 | Jun 2023 → Jun 2028 expected | neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVS-3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05672459 ↗ |
| Modality | Cell therapy | “IVS-3001 is an autologous CAR-T cell therapy targeting human leukocyte antigen (HLA-G)” NCT05672459 ↗ |
| Target | HLA-G | “targeting human leukocyte antigen (HLA-G)” NCT05672459 ↗ |